Abstract:Rationale: Vascular calcification (VC) is a marker of the severity of atherosclerotic disease. Hormones play important roles in regulating calcification; estrogen and parathyroid hormones exert opposing effects, the former alleviating VC and the latter exacerbating it. To date no treatment strategies have been developed to regulate clinical VC. Objective: The objective of this study was to investigate the effect of growth hormone–releasing hormone (GHRH) and its agonist (GHRH-A) on the blocking of VC in a mouse model. Methods and Results: Young adult osteoprotegerin-deficient mice were given daily subcutaneous injections of GHRH-A (MR409) for 4 weeks. Significant reductions in calcification of the aortas of MR409-treated mice were paralleled by markedly lower alkaline phosphatase activity and a dramatic reduction in the expression of transcription factors, including the osteogenic marker gene Runx2 and its downstream factors, osteonectin and osteocalcin. The mechanism of action of GHRH-A was dissected in smooth muscle cells isolated from human and mouse aortas. Calcification of smooth muscle cells induced by osteogenic medium was inhibited in the presence of GHRH or MR409, as evidenced by reduced alkaline phosphatase activity and Runx2 expression. Inhibition of calcification by MR409 was partially reversed by MIA602, a GHRH antagonist, or a GHRH receptor–selective small interfering RNA. Treatment with MR409 induced elevated cytosolic cAMP and its target, protein kinase A which in turn blocked nicotinamide adenine dinucleotide phosphate oxidase activity and reduced production of reactive oxygen species, thus blocking the phosphorylation of nuclear factor κB (p65), a key intermediate in the ligand of receptor activator for nuclear factor-κ B-Runx2/alkaline phosphatase osteogenesis program. A protein kinase A–selective small interfering RNA or the chemical inhibitor H89 abolished these beneficial effects of MR409. Conclusions: GHRH-A controls osteogenesis in smooth muscle cells by targeting cross talk between protein kinase A and nuclear factor κB (p65) and through the suppression of reactive oxygen species production that induces the Runx2 gene and alkaline phosphatase. Inflammation-mediated osteogenesis is thereby blocked. GHRH-A may represent a new pharmacological strategy to regulate VC.

Angiotensin-(1-7) Inhibits Vascular Calcification in Rats

Angiotensin-(1–7) Regulates Angiotensin II-induced VCAM-1 Expression on Vascular Endothelial Cells

Abstract 160: Angiotensin-(1-7) Decreases the Pro-inflammatory Effects of Prorenin in Hypothalamic Microglia

Aspirin Relieves the Calcification of Aortic Smooth Muscle Cells by Enhancing the Heat Shock Response

Inhibition of angiotensin II and blockade of endothelin receptors reduce arterial calcification in rats

Endogenous aldosterone is involved in vascular calcification in rat.

Angiotensin II-induced Matrix Metalloproteinase-8 is Regulated by Angiotensin-(1-7) in Vascular Smooth Muscle Cells

Angiotensin-(1-7) Attenuates Angiotensin II-Induced ICAM-1, VCAM-1, and MCP-1 Expression via the MAS Receptor Through Suppression of P38 and NF-κB Pathways in HUVECs

Role of Endogenous Angiotensin II in the Pathogenesis of Aortic Calcification in Rats

C-Type Natriuretic Peptide Inhibiting Vascular Calcification Might Involve Decreasing Bone Morphogenic Protein 2 and Osteopontin Levels

DIFFERENT EFFECTS OF ANGIOTENSIN II AND ANGIOTENSIN-(1–7) ON ENDOTHELIAL VCAM-1 EXPRESSION DURING ATHEROSCLEROSIS

The Role and Possible Mechanism of Aldosterone in the Vascular Calcification of Rats

Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells

Counteraction Between Angiotensin II and Angiotensin-(1–7) Via Activating Angiotensin Type I and Mas Receptor on Rat Renal Mesangial Cells

Knockdown of Estrogen‐related Receptor Α Inhibits Valve Interstitial Cell Calcification in Vitro by Regulating Heme Oxygenase 1

Abstract 3145: Inactivating the Adenosine 2A Receptor Reduces Vascular Calcification Through Modulating Osteogenic Differentiation of Vascular Cells

Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and Its Agonists

Blocking VCAM-1 Prevents Angiotensin II-Induced Hypertension and Vascular Remodeling in Mice

Adrenomedullin up-regulates osteopontin and attenuates vascular calcification via the cAMP/PKA signaling pathway

Wnt1 inhibits vascular smooth muscle cell calcification by promoting ANKH expression.

Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein